Abstract
Introduction:
Numerous psychological factors are believed to play a pivotal role in the development and maintenance of persistent somatic symptoms (PSS) in all fields of medicine. However, very few of these factors have been empirically investigated in relation to PSS. The aim of this study is firstly to propose a framework and define search terms for systematic reviews on the empirical evidence and diagnostic value of psychological risk factors for PSS and PSS-related outcomes (PSY-PSS). Secondly, the application of the framework is illustrated using the example of a systematic review on the relevance of psychological factors in somatic symptom disorders (SSD; DSM-5) and bodily distress disorders (BDD; ICD-11).
Methods:
Following a narrative review approach, two comprehensive lists of search terms to identify studies in (1) relevant patient groups with PSS and (2) relevant psychological factors were generated by reviewing the current literature and employing an iterative process of internal revision and external expert feedback.
Results:
We identified 83 relevant symptoms, syndromes and disorders for which we defined a total of 322 search terms (list 1). We further comprised 120 psychological factors into 42 subcategories and 7 main categories (list 2). The introduced lists can be combined to conduct systematic reviews on one or more specific psychological factors in combination with any symptom, syndrome or disorder of interest. A protocol of the application of this framework in a systematic review and meta-analysis on psychological etiological factors of SSD and BDD is presented following the PRISMA guidelines.
Discussion:
This framework will help to gather systematic evidence on psychological factors in order to improve the understanding of the etiology of PSS, to refine future diagnostic conceptualizations of PPS, and to develop optimized mechanism-based interventions for individuals with PPS and related syndromes and disorders.
Introduction
Persistent somatic symptoms (PSS) are a common phenomenon. Up to 80% of the general population report one or more somatic symptoms over the course of the past 4 weeks (1–3). While in most cases symptoms are remittent, they persist in approximately one fourth of all patients. These symptoms often impair patients’ lives even years after initial appearance, regardless of their origin or underlying physiopathology (4, 5). PSS are common in almost all medical specialties and many times remain “medically unexplained.” Even though the term “medically unexplained symptoms” (MUS) has been used in clinical practice and research for many years, the concept was considered problematic since the reliability of assessing whether or not there is a pathophysiological explanation for a certain symptom is notoriously poor. Furthermore, the concept reinforced a mind–body-dualism, the fact that a symptom cannot be “medically explained” does not imply that it must be part of a psychiatric disorder (6). Regardless of their etiology, PSS pose a challenge in medicine regarding diagnostic accuracy, early detection and appropriate treatment. Repeated medical examinations and invasive treatments are common, despite being time-consuming and costly (7).
Current evidence regarding the etiology of PSS defines biomedical and psychosocial predisposing, triggering, and maintaining/aggravating factors (8–10). Thus, a thorough diagnostic process based on a biopsychosocial perspective is essential for successful treatment (11, 12). Most etiological models of somatoform and functional disorders include psychological factors involving cognitive-perceptual mechanisms such as amplified perception of bodily sensations or selective attention processes, affective factors such as illness anxiety or emotion regulation deficits, and behavioral mechanisms such as avoidance (13–16). The ICD-10 and DSM-IV classification of somatoform disorders did, however, not include any psychological criteria, and diagnosis was thus merely based on the presence of symptoms in the absence of a medical explanation (17, 18). Similarly, the diagnostic conceptualizations of the most common functional syndromes, i.e., irritable bowel syndrome (19), fibromyalgia (20) and chronic fatigue syndrome (21), do not contain any psychological factors at all.
In the revised diagnostic concepts of somatic symptom and related disorders in DSM-5 (22), and bodily distress disorders in ICD-11 (23), psychological criteria are now included. Somatic Symptom Disorder (SSD) is defined by one or more persistent somatic symptom(s) that are distressing or result in significant disruption of daily life. Symptoms may or may not be medically explained (24). The new diagnostic concepts now require that the somatic complaints are accompanied by excessive and disproportionate health-related thoughts, feelings, and behaviors.
The introduction of these psychological criteria was supported by evidence suggesting it is not the somatic symptoms per se that result in suffering and increased health care needs, but rather how patients interpret and act upon the symptoms (25, 26). In fact, psychological features such as health anxiety and catastrophizing are significant determinants of disability, health care utilization, and predict disease course and treatment outcome (27–29). Experts in the field thus welcomed the inclusion of psychological criteria to the diagnostic classification of PSS in DSM-5 and ICD-11 (24, 25, 30). A recently published scoping review on the empirical evidence of somatic symptom disorder summarized the generally good reliability, validity and clinical utility of the DSM-5 criteria (24). However, it was also pointed out that ‘the greatest need for improvement of the SSD diagnostic criteria appears to be measurable and more precise diagnostic B-criteria’ (24), i.e., the psychological ‘positive’ criteria of the diagnosis. Further, the choice of the psychological criteria has been criticized (31), and the relevance of the clinical context and subjective interpretation of these criteria was highlighted (32, 33).
There is empirical evidence for a long list of further psychological variables relevant to PSS and related conditions, that have not been included in the DSM-5 and ICD-11 diagnostic criteria. The following paragraph will provide several relevant examples. Regarding behavioral factors, fear avoidance behavior is among the best predictors for the transition of acute to chronic pain (34). For patients with multiple somatic symptoms, avoiding situations that challenge the body is one of the most powerful variables distinguishing highly disabled patients from those with low health care needs, even if both groups report a similar number of somatic symptoms (35). Behavioral avoidance is furthermore related to physical inactivity and subsequent deconditioning (36). As cognitive determinants of PSS, ruminations about physical complaints, self-concept of bodily weakness, and subjective low symptom tolerance have been suggested (35). Affective symptoms and traits such as negative affectivity, desperation, hope-and helplessness, anger related to somatic symptoms, as well as deficits in emotion regulation, in particular alexithymia, are further relevant factors in the maintenance of somatic symptoms (37). Empirical data also support the importance of selective attention processes, or amplified perception of bodily sensations in the sense of somatosensory amplification in the perseverance of symptoms (13, 38–40). Further potentially aggravating factors of PSS arise from unsatisfying interactions between patients and the health care system, negative illness perceptions, and treatment experiences (41), which oftentimes result in unnecessary and potentially harmful extensive utilization of health care (42).
Since most studies investigate singular psychological factors and focus on singular PSS-related diagnostic conditions, the data for most of these psychological criteria are not sufficiently robust. As the evidence has not been systematically reviewed, there is no consensus on their potential justification in the diagnostic classifications of PSS and related syndromes and disorders. In summary, one of the greatest needs for the improvement of the diagnostic classification for PSS across medical fields is to identify the evidence on those psychological factors. This evidence should either show that a specific psychological factor is able to discriminate patients suffering from PSS and related conditions from healthy or clinical controls, or be significantly associated to PSS-relevant clinical outcomes such as symptom severity, functional impairment, quality of life or health care utilization. In the sense of a risk factor, a psychological factor should be predictive for these outcomes or for the development or maintenance of the symptoms and conditions themselves. This framework provides the tools to systematically collect this evidence.
Aims and objectives
It is our overall aim to systematically review the scientific evidence of pre-defined psychological variables in relevance to PSS, somatic symptom disorder, bodily distress disorder, functional syndromes and related disorders. This will require a number of individual systematic reviews and meta-analyses addressing different psychological variables in combination with different PSS and related syndromes and disorders. Results will ultimately provide an improved etiological understanding of PSS, and consequently be a starting point for an improvement of diagnostic conceptualizations, diagnostic validity and the development of mechanism-based interventions.
Within this paper, we pursue two aims. First, we present a framework for systematic reviews in order to evaluate the empirical evidence and diagnostic value of psychological correlates and risk factors for PSS and related syndromes and disorders (PSY-PSS). To this end, we developed two lists of relevant search terms in this research area, i.e., an extensive list of all relevant search terms for PSS and related syndromes and disorders and a comprehensive list with potentially relevant psychological factors. Both lists can be combined to conduct systematic reviews on specific psychological factors and specific PSS and related syndromes or disorders and thus provide researchers with a common search matrix as starting point.
Second, based on our PSY-PSS framework, we present the study protocol of a first systematic review on the identification of psychological associates and risk factors for the most recent diagnostic concepts of PSS, i.e., somatic symptom disorder (SSD; according to DSM-5) and bodily distress disorder (BDD; according to ICD-11). In the future, we aim to follow up with further systematic reviews on the relevance of certain psychological factors such as negative affectivity or avoidance behavior in other PSS-related syndromes and disorders, such as irritable bowel syndrome, chronic fatigue syndrome, or fibromyalgia.
Methods and results
In a first step, we identified the diagnostic terms used for PSS and related syndromes and disorders throughout various fields of medicine. In a second step, we narratively reviewed the current literature to identify potentially relevant psychological associates and risk factors for PSS and related syndromes and disorders.
Lists of PSS and related syndromes and disorders and identified psychological factors
PSS and related syndromes and disorders
Our goal was to create a comprehensive list of diagnostic terms used for PSS and related syndromes and disorders in research and clinical practice. Thereby, we aimed to cover all diagnostic classifications that are based on the presence of persistent somatic symptoms, regardless of their etiology. First, we included all psychiatric and general diagnostic concepts, i.e., somatoform disorders (DSM-IV and ICD-10), somatic symptom and related disorders (DSM-5), bodily distress disorders (ICD-11), and so-called “medically unexplained symptoms.” Second, we included functional somatic syndromes from all medical specialties (e.g., irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome). Third, in addition to clinically established diagnoses, we also included syndromes from specific health care systems, such as bodily distress syndrome (43), wind turbine syndrome, or chronic whiplash syndrome, and Long Covid.
Our list is based on a previous list created for a systematic review on early interventions for PSS (44), which in turn was based on a list published earlier by Henningsen et al. (45). We reviewed this list with a team of experts (MSM, AT, AS, PH), added missing terms, and rearranged the terms into diagnostic subgroups based on symptom domains, i.e., by conditions and medical specialties (see Table 1). As the terminology for PSS and related syndromes and disorders differs substantially across countries and medical specialties, we tried to provide a comprehensive list of all clinically and scientifically terms used in Western countries (6, 46). The full list includes 83 conditions with 322 terms (Supplementary material Table 1).
Table 1
| Specialty | Condition |
|---|---|
| General (non-specific) terms | Functional |
| General practitioner | Subjective symptoms, medically unexplained symptoms |
| Psychiatry/psychosomatic medicine | Dissociative disorders, somatoform disorder, somatization disorder, pain disorder, conversion disorder, somatic symptom disorder, bodily distress disorder, culture-bound syndrome |
| Allergology | Food intolerance, multiple chemical sensitivity, sick building syndrome, Persian Gulf syndrome, amalgam hypersensitivity, Implant intolerance, prothesis intolerance, aerotoxic syndrome, wind turbine syndrome, electromagnetic hypersensitivity |
| Anesthesiology | Idiopathic pain, chronic postoperative pain |
| Cardiology | Atypical chest pain, palpitations with normal investigations, syndrome X |
| Dermatology | Psychogenic skin disease |
| Endocrinology | Hypoglycemia |
| Gastroenterology | Functional gastrointestinal disorders, disorders of the gut-brain-interaction, functional bowel syndrome, nonulcer dyspepsia, functional abdominal pain, functional colon disease, functional disorders of swallowing, globus syndrome |
| Gynecology and urology | Premenstrual syndrome, functional urologic disorders, paruresis, dysfunctional voiding, idiopathic overactive bladder, interstitial cystitis, urethral syndrome, chronic pelvic pain syndrome, pelvic arthropathy |
| Infectiology | Chronic lyme disease, candida hypersensitivity, chronic rhinopharyngitis |
| Neurology | Functional seizures, functional voice disorder, functional motor disorder, functional eye movement disorder, functional facial movement disorder, functional tongue movement disorder, functional sensory symptoms, functional visual symptoms, functional speech disorder, functional memory disorder, functional cognitive disorder, functional dizziness, functional stroke, tension headache, atypical face pain, central sensitivity syndrome, post-concussion syndrome, chronic fatigue syndrome, myalgic encephalomyelitis, neurasthenia, post-viral fatigue syndrome |
| Oral medicine/otorhinolaryngology | Temporomandibular joint disorder, atypical odontalgia, psychogenic gagging, burning mouth, bruxism |
| Orthopedics | Repetitive strain injury, chronic whiplash syndrome |
| Respiratory medicine | Hyperventilation syndrome |
| Rheumatology | Fibromyalgia, chronic low back pain, chronic pain, persistent pain, chronic intractable benign pain syndrome |
List of medical specialties and conditions (n = 83) included in the search list on PSS and related syndromes and disorders.
Psychological risk factors
Regarding the psychological risk factors, we employed a narrative review approach by searching the scientific literature, overview articles and books on the etiology, diagnosis and treatment of PSS, somatoform disorders and functional syndromes. A more systematic approach to derive at the psychological factors would have been desirable, but was not possible due to the heterogeneity of concepts and empirical evidence. The identified terms were reviewed and amended by experts and synthesized into categories in an iterative process. An overview of this process can be found in Figure 1 and will be described in further detail below.
Figure 1
Process of developing the list of psychological factors. The numbers within the circles represent the number of terms included at the various stages.
First, we screened current literature and overview articles to summarize known and assumed psychological factors with an influence on the development and maintenance of PSS, somatoform disorders, somatic symptom disorders, medically unexplained symptoms, and functional syndromes (10, 26, 30, 40, 47, 48). We used this list of n = 62 identified psychological variables as a starting point to review further literature until we reached saturation (total number of variables: n = 152). A group of three experts in the field of PSS (AT, MSM, PH) reviewed this list and classified each term within a subcategory. We excluded non-psychological factors, i.e., sociodemographic factors such as age or gender, or social factors such as social support, resulting in n = 128 variables. In a next step, we asked two independent international experts (BL and MK) to rate 128 psychological factors based on their relevance for PSS and related syndromes and disorders (both from a research and clinical perspective) and fit to subcategory, and asked for further potentially missing variables. Incorporation of expert feedback led to a total of n = 131 variables. We organized the terms into main and subcategories. After a last internal review and discussion (AT, MSM, PH, AS), we agreed on a list of 120 psychological variables in 42 subcategories and 7 main categories (see Figure 2; full list in Supplementary material Table 2).
Figure 2
Tree diagram of relevant psychological variables potentially associated with PSS and related syndromes and disorders.
Resulting research matrix for investigating psychological factors in PSS and related syndromes and disorders
We propose the application of the two lists in the sense of a framework that enables researchers to generate comparable evidence on psychological factors relevant to PSS and related syndromes and disorders. In order to foster common knowledge, both lists shall be freely available to other research groups, and are shared within the Open Science Framework (49, 50). The search strategy was developed to use each psychological variable (list 2) as a keyword in combination with the terms of the disorder-specific synonyms (list 1) using the logical operator AND. Psychological terms should be combined using the logical operator OR. Table 2 displays the idea of combining both lists in order to improve the evidence on psychological correlates and risk factors of PSS and related syndromes and disorders.
Table 2
| Psychological factors (examples) | PSS terms (examples) | ||||
|---|---|---|---|---|---|
| Somatic symptom disorder | Irritable bowel syndrome | Fibromyalgia | … | ||
| Behavioral | Avoidance behavior | Avoidance behavior in SSD | … | ||
| Affective | Alexithymia | … | |||
| Cognitive | Catastrophizing | ||||
| … | … | ||||
Matrix for systematic searches to improve the evidence on psychological factors relevant to PSS and related syndromes and disorders.
Application example of the PSY-PSS framework: Study protocol for a systematic review on the evidence of psychological concepts with prognostic validity in somatic symptom disorder and bodily distress disorder
Based on the generated framework, we aim to conduct a systematic review on the empirical evidence of psychological correlates and risk factors in the diagnoses according to the current classification systems DSM-5 (somatic symptom disorder; SSD) and ICD-11 (bodily distress disorder; BDD). The method and reporting of the review will be conducted in accordance to the guidelines outlined in the PRISMA statement (51).
Search strategy for the identification of relevant studies
Search terms will comprise of SSD or BDD, respectively, in combination with all terms from our list of psychological risk factors (Supplementary material Tables 1, 2). The literature search will include records from the following databases: PubMed (NCBI), PsycINFO (Ovid), Web of Science (Clarivate Analytics), as well as the Cochrane Database of Systematic Reviews.
We will review titles and abstracts of all identified studies. Due to the scope of the study and to ensure that we exclude outdated data, we will only include studies that were published after initial release of the DSM-5 criteria, i.e., from 2009 and onwards. We will only include studies published in English or German language in peer-reviewed journals.
Criteria for inclusion and exclusion of studies in the review
In order to be included in the planned review, identified studies must contain original data or be systematic reviews. Included studies or reviews must be based on patient populations diagnosed with SSD or BDD. Thereby, diagnoses should be given through either diagnostic interviews, clinical judgment, or validated screening measures. They should provide observational cross-sectional or longitudinal data on the association of psychological variables on diagnosis or disorder-relevant outcomes, i.e., symptom severity, impairment or quality of life. Psychological factors should be measured quantitatively. We will exclude studies that refer to former classifications of PSS, i.e., somatoform disorders, or use unclear methodology to provide diagnoses of SSD or BDD.
Quality assessment
The quality of all studies included in the analysis will be evaluated using the Effective Public Health Practice Project Quality Assessment Tool (52, 53). Two reviewers will evaluate the studies with regard to selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts. Any disagreement among the reviewers will be resolved with discussion and input from a third reviewer, if necessary.
Study coding and extraction of data
Two reviewers will review the titles and abstracts of the identified studies independently and ensure duplicates are removed. Decisions for or against inclusion will be based on the standardized inclusion/exclusion criteria. If not excluded in the initial round, full manuscripts will be retrieved, or in case where information in the title and abstract is not sufficient to exclude the study. In the second round, studies will be re-reviewed, data extracted using the automation software package Rayyan (54) and results will be compared and discussed by both reviewers. In case of disagreement, a third independent reviewer will be asked for mediation. The following data will be extracted from each included study (see Table 2):
-
Study characteristics: design, setting, primary aim of the study etc.
-
Diagnosis investigated in the study and operationalization of diagnostic criteria (SSD or BDD)
-
Psychological factors included in the study and operationalization of constructs (employed self-report instruments)
-
Disorder-relevant outcomes and their assessment along with effect sizes (if reported)
Descriptions of outcomes
In order to determine the relevance of the psychological variables as associates or risk factors for PSS in SSD and/or BDD, diagnostic status, somatic symptom severity, impairment, quality of life, and health care utilization will serve as outcomes. We want to answer the following three research questions:
-
In which psychological factors do patients with SSD/BDD differ compared to control groups?
-
How are psychological factors associated with disorder-relevant outcomes such as symptom severity, functional impairment, health care utilization, and quality of life?
-
Which psychological factors are predictive for the development or maintenance of SSD/BDD?
Data synthesis and planned analyses
Data of study characteristics and methods employed will be descriptively summarized in Tables 3, 4.
Table 3
| Study authors (year) | Type of study | Study characteristics | Diagnosis and assessment | Psychological variables (measurement tool) | Outcome(s) | Effect size |
|---|---|---|---|---|---|---|
| Example et al. (2015) | RCT on DBT therapy in patients with SSD | 200 patients with SSD undergoing DBT vs. control (waiting list) | SSD: Cut-off scores (PHQ-15 ⩾ 15 and SSD-12 ⩾ 15) | Depression (PHQ-9), Somatosensory amplification (SSAS) | Primary: Diagnosis present at follow-up (cut-off scores), Secondary: symptom severity (NRS) | PHQ-9: d = xx, SSAS: d = yy; NRS: d = zz |
| Illustration (2016) | Cohort study on the development of BDD and the association with somatosensory amplification/traumatic childhood experiences | Cohort of 342 patients (BDD vs. no BDD) | BDD: clinical judgment | Somatosensory amplification (SSAS), Traumatic experience (ACE) | Somatosensory amplification score in BDD sample | r = aa (SSAS and ACE), d = bb |
Information on included studies with fictional examples.
DBT, Dialectic Behavioral Therapy; SSD, Somatic Symptom Disorder; BDD, Bodily Distress Disorder; PHQ-9, Patient Health Questionnaire-9; PHQ-15, Patient Health Questionnaire-15; SSAS, Somatosensory Amplification Scale; SF-12, Short Form 12 Health Survey; NRS, numeric rating scale; ACE, Adverse Childhood Experiences Questionnaire.
Table 4
| Category | Sub-category | Variable | Studies providing data | Outcome(s) | Effect sizes of variable and outcome association |
|---|---|---|---|---|---|
| Psychopathology | Depression | Depressive symptoms | Example et al. (2015) | SSD diagnosis | d = xx |
| Cognitive | Attentional processes | Somatosensory amplification | Example et al. (2015), Illustration (2016) | SSD diagnosis, SSAS score in BDD sample | d = yy, d = bb |
Psychological variables and effect sizes of associations on disorder-relevant factors.
SSD, somatic symptom disorder; BDD, bodily distress disorder.
While Table 3 includes an overview of all included studies, Table 4 lists the empirical evidence for each psychological factor identified throughout the review process.
If at least three studies are available for the same outcome and psychological variable, meta-analyses will be performed. If meta-analysis is not appropriate, we will report outcomes narratively. For conducting meta-analyses we will use the statistical software R (version 4.1.1) (55). Due to anticipated heterogeneity of diagnoses, populations and outcome measures included in our data, we do not expect to conceive collected effect sizes to represent a single population effect size. We will thus conduct random-effects analyses for each outcome. We will compute weights using the inverse-variance method. Between-study variance (τ2) will be estimated the method of restricted maximum likelihood (56, 57). We will report a summary effect and its corresponding 95% confidence interval using the Knapp-Hartung method and its 95% prediction interval (58, 59).
Study registration
The framework for this review project has been registered with PROSPERO [registration number CRD42022302014 (60)]. Both lists comprising the search terms for the psychological variables and the terms and synonyms for PSS and related syndromes and disorders are available on the Open Science Framework OSF (49).
Discussion
With this publication, we provide a framework to systematically review the current evidence on psychological associates and risk factors in persistent somatic symptoms and related syndromes and disorders. We further illustrate the use of this framework by presenting the protocol for a first systematic review on the evidence of the associates and risk factors of psychological factors in SSD and BDD, the diagnostic classifications currently in use in DSM-5 and ICD-11.
Thereby, we hope to provide sound evidence for the ongoing debate on the relevance of psychological features for the diagnosis of PSS and related syndromes and disorders. This debate has been going on since the introduction of the DSM-5 SSD criteria, with critics arguing that psychological features are neither necessary nor sufficient to make valid diagnoses in patients with PSS and related syndromes and disorders (61, 62). However, there is evidence that psychological features predict outcomes relevant to PSS, such as stability of diagnosis, health care utilization, or quality of life (24, 27). As such, a recently proposed alternative classification for PSS, i.e., “functional somatic disorders,” does not rely on psychological features, but proposes their additional specification, thereby giving priority to features that are prognostic in terms of severity/duration or guiding treatment (61).
In this sense, the results to be derived from our framework will provide a starting point for an improved mechanistic understanding and refinement of future diagnostic conceptualizations for PSS and related syndromes and disorders. The identification of relevant psychological factors holds the great chance that these are modifiable and, therefore, a promising gateway to improve the currently only moderately effective treatment for PSS and related syndromes and disorders (37, 47, 63). Targeted interventions for prevention, early identification and treatment of PSS and related syndromes and disorders can only be developed once psychological risk factors and mechanisms are better understood.
A major strength of our framework is that it provides a valid and comprehensive foundation that has been derived through a sound systematic approach. It will enable researchers to flexibly carry out systematic reviews with broad yet also specific aims (i.e., selection of only a sub-group of psychological variables and/or diagnoses). As major limitations, we acknowledge that both lists may not be complete, are mostly limited to current evidence from Western countries, and need to be updated regularly based on new evidence. We thus advise interested researcher to always visit the ORF for the latest versions of both PSY-PSS lists (49).
Also, the classification of the psychological constructs into (sub-) categories may be debatable, as it is based on an inductive process of expert opinion. However, we believe our framework could be a useful starting point for consecutive reviews that will improve the current understanding and knowledge in diagnosing and treating PSS and related syndromes and disorders. Thus, we explicitly invite research groups from different medical and psychological specialties to use and further develop the PSY-PSS framework with respect to their individual research questions. The PSY-PSS framework can further be extended to investigate evidence on psychological factors in symptom-based medical diseases such as inflammatory bowel disease or rheumatologic conditions.
The ongoing debate on DSM-5 somatic symptom disorder and the upcoming implementation of ICD-11 in health-care systems worldwide requires additional research. ICD-11 is a classification system which is designed to be open to change and adaptations, and thus reliant on constantly updated empirical evidence. In the end, not only research, but also especially clinical care will benefit from a better knowledge of what to include in the so-called “psycho-bundle” of PSS and related syndromes and disorders.
Funding
We acknowledge financial support from the Open Access Publication Fund of UKE-Universitätsklinikum Hamburg-Eppendorf- and DFG – German Research Foundation.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
AT, MS-M, and PH were involved in the concept and design of the study. AT and PH conducted the preliminary search. Feedback on all variables was provided by BL and MK. Further internal discussion involved AT, MS-M, PH, and AS. PH wrote the draft of this manuscript. AT, MS-M, BL, MK, and AS provided valuable revisions. All authors contributed to the article and approved the submitted version.
Acknowledgments
The PSY-PSS framework was inspired and influenced by the scientific exchange within EURONET-SOMA, the European Network to Improve Diagnostic, Treatment and Health Care for Patients with Persistent Somatic Symptoms (https://www.euronet-soma.eu/). We would like to thank Sophia Völcker, Efim Lenz and Anna Borgmann for their competent and reliable support in finalizing the search term lists.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1142484/full#supplementary-material
References
1.
Steinbrecher N Hiller W . Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. Gen Hosp Psychiatry. (2011) 33:318–26. doi: 10.1016/j.genhosppsych.2011.05.002
2.
Kroenke K . Patients presenting with somatic complaints: epidemiology, psychiatric co-morbidity and management. Int J Methods Psychiatr Res. (2003) 12:34–43. doi: 10.1002/mpr.140
3.
Hinz A Ernst J Glaesmer H Brahler E Rauscher FG Petrowski K et al . Frequency of somatic symptoms in the general population: normative values for the patient health Questionnaire-15 (PHQ-15). J Psychosom Res. (2017) 96:27–31. doi: 10.1016/j.jpsychores.2016.12.017
4.
Löwe B Spitzer RL Williams JB Mussell M Schellberg D Kroenke K . Depression anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry. (2008) 30:191–9. doi: 10.1016/j.genhosppsych.2008.01.001
5.
Nimnuan C Hotopf M Wessely S . Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res. (2001) 51:361–7. doi: 10.1016/S0022-3999(01)00223-9
6.
Creed F Guthrie E Fink P Henningsen P Rief W Sharpe M et al . Is there a better term than “medically unexplained symptoms”?J Psychosom Res. (2010) 68:5–8. doi: 10.1016/j.jpsychores.2009.09.004
7.
Konnopka A Kaufmann C König HH Heider D Wild B Szecsenyi J et al . Association of costs with somatic symptom severity in patients with medically unexplained symptoms. J Psychosom Res. (2013) 75:370–5. doi: 10.1016/j.jpsychores.2013.08.011
8.
Klaus K Rief W Brähler E Martin A Glaesmer H Mewes R . The distinction between “medically unexplained” and “medically explained” in the context of somatoform disorders. Int J Behav Med. (2013) 20:161–71. doi: 10.1007/s12529-012-9245-2
9.
Joustra ML Janssens KAM Bültmann U Rosmalen JGM . Functional limitations in functional somatic syndromes and well-defined medical diseases. Results from the general population cohort LifeLines. J Psychosom Res. (2015) 79:94–9. doi: 10.1016/j.jpsychores.2015.05.004
10.
Henningsen P Gundel H Kop WJ Löwe B Martin A Rief W et al . Persistent physical symptoms as perceptual dysregulation: a neuropsychobehavioral model and its clinical implications. Psychosom Med. (2018) 80:422–31. doi: 10.1097/PSY.0000000000000588
11.
Kroenke K . A practical and evidence-based approach to common symptoms: a narrative review. Ann Intern Med. (2014) 161:579–86. doi: 10.7326/M14-0461
12.
Kisely S Simon G . An international study comparing the effect of medically explained and unexplained somatic symptoms on psychosocial outcome. J Psychosom Res. (2006) 60:125–30. doi: 10.1016/j.jpsychores.2005.06.064
13.
Barsky AJ Wyshak G . Hypochondriasis and somatosensory amplification. Br J Psychiatry. (1990) 157:404–9. doi: 10.1192/bjp.157.3.404
14.
Löwe B Andresen V Van den Bergh O Huber TB von dem Knesebeck O Lohse AW et al . Persistent SOMAtic symptoms ACROSS diseases—from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). BMJ Open. (2022) 12:e057596. doi: 10.1136/bmjopen-2021-057596
15.
Mayou R Kirmayer LJ Simon G Kroenke K Sharpe M . Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatr. (2005) 162:847–55. doi: 10.1176/appi.ajp.162.5.847
16.
Sharpe M Mayou R Walker J . Bodily symptoms: new approaches to classification. J Psychosom Res. (2006) 60:353–6. doi: 10.1016/j.jpsychores.2006.01.020
17.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). Washington DC: American Psychiatric Association. (2000).
18.
World Health Organization (WHO) . The ICD-10 Classification of Mental and Behavioral Disorders. Genève, Switzerland: World Health Organization (2004).
19.
Lacy BE Patel NK . Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. (2017) 6:99. doi: 10.3390/jcm6110099
20.
Wolfe F Häuser W . Fibromyalgia diagnosis and diagnostic criteria. Ann Med. (2011) 43:495–502. doi: 10.3109/07853890.2011.595734
21.
Fukuda K Straus SE Hickie I Sharpe MC Dobbins JG Komaroff A et al . The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. (1994) 121:953–9. doi: 10.7326/0003-4819-121-12-199412150-00009
22.
American Psychiatric Association . Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Association (2013).
23.
World Health Organization . International Classification of Diseases for Mortality and Morbidity Statistics 11th Revision (2018).
24.
Löwe B Levenson J Depping M Hüsing P Kohlmann S Lehmann M et al . Somatic symptom disorder: a scoping review on the empirical evidence of a new diagnosis. Psychol Med. (2022) 52:632–48. doi: 10.1017/S0033291721004177
25.
Dimsdale JE Creed F Escobar J Sharpe M Wulsin L Barsky A et al . Somatic symptom disorder: an important change in DSM. J Psychosom Res. (2013) 75:223–8. doi: 10.1016/j.jpsychores.2013.06.033
26.
Rief W Mewes R Martin A Glaesmer H Braehler E . Are psychological features useful in classifying patients with somatic symptoms?Psychosom Med. (2010) 72:648–55. doi: 10.1097/PSY.0b013e3181d73fce
27.
Voigt K Wollburg E Weinmann N Herzog A Meyer B Langs G et al . Predictive validity and clinical utility of DSM-5 somatic symptom disorder: prospective 1-year follow-up study. J Psychosom Res. (2013) 75:358–61. doi: 10.1016/j.jpsychores.2013.08.017
28.
Schumacher S Rief W Klaus K Brähler E Mewes R . Medium-and long-term prognostic validity of competing classification proposals for the former somatoform disorders. Psychol Med. (2017) 47:1719–32. doi: 10.1017/S0033291717000149
29.
Wollburg E Voigt K Braukhaus C Herzog A Löwe B . Construct validity and descriptive validity of somatoform disorders in light of proposed changes for the DSM-5. J Psychosom Res. (2013) 74:18–24. doi: 10.1016/j.jpsychores.2012.09.015
30.
Voigt K Nagel A Meyer B Langs G Braukhaus C Löwe B . Towards positive diagnostic criteria: a systematic review of somatoform disorder diagnoses and suggestions for future classification. J Psychosom Res. (2010) 68:403–14. doi: 10.1016/j.jpsychores.2010.01.015
31.
Klaus K Rief W Brähler E Martin A Glaesmer H Mewes R . Validating psychological classification criteria in the context of somatoform disorders: a one-and four-year follow-up. J Abnorm Psychol. (2015) 124:1092–101. doi: 10.1037/abn0000085
32.
Cao J Wei J Fritzsche K Toussaint AC Li T Jiang Y et al . Prevalence of DSM-5 somatic symptom disorder in Chinese outpatients from general hospital care. Gen Hosp Psychiatry. (2020) 62:63–71. doi: 10.1016/j.genhosppsych.2019.11.010
33.
Huang WL Chen IM Chang FC Liao SC . Somatic symptom disorder and undifferentiated somatoform disorder, which is broader? Response to clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS). J Psychosom Res. (2016) 89:114–5. doi: 10.1016/j.jpsychores.2016.07.014
34.
Chou R Shekelle P . Will this patient develop persistent disabling low back pain?J Am Med Assoc. (2010) 303:1295–302. doi: 10.1001/jama.2010.344
35.
Voigt K Wollburg E Weinmann N Herzog A Meyer B Langs G et al . Predictive validity and clinical utility of DSM-5 somatic symptom disorder - comparison with DSM-IV somatoform disorders and additional criteria for consideration. J Psychosom Res. (2012) 73:345–50. doi: 10.1016/j.jpsychores.2012.08.020
36.
Vlaeyen JW Crombez G Linton SJ . The fear-avoidance model of pain. Pain. (2016) 157:1588–9. doi: 10.1097/j.pain.0000000000000574
37.
Kleinstäuber M Gottschalk J Berking M Rau J Rief W . Enriching cognitive behavior therapy with emotion regulation training for patients with multiple medically unexplained symptoms (ENCERT): design and implementation of a multicenter, randomized, active-controlled trial. Contemp Clin Trials. (2016) 47:54–63. doi: 10.1016/j.cct.2015.12.003
38.
Rief W Martin A . How to use the new DSM-5 somatic symptom disorder diagnosis in research and practice: a critical evaluation and a proposal for modifications. Annu Rev Clin Psychol. (2014) 10:339–67. doi: 10.1146/annurev-clinpsy-032813-153745
39.
Van Den Houte M Bogaerts K Van Diest I De Bie J Persoons P Van Oudenhove L et al . Perception of induced dyspnea in fibromyalgia and chronic fatigue syndrome. J Psychosom Res. (2018) 106:49–55. doi: 10.1016/j.jpsychores.2018.01.007
40.
Rief W Broadbent E . Explaining medically unexplained symptoms-models and mechanisms. Clin Psychol Rev. (2007) 27:821–41. doi: 10.1016/j.cpr.2007.07.005
41.
Rief W. . Somatisierungsstörung. Verhaltenstherapiemanual. Springer; (2011). p. 655–659.
42.
Henningsen P . Management of somatic symptom disorder. Dialogues Clin Neurosci. (2018) 20:23–31. doi: 10.31887/DCNS.2018.20.1/phenningsen
43.
Budtz-Lilly A Schröder A Rask MT Fink P Vestergaard M Rosendal M . Bodily distress syndrome: a new diagnosis for functional disorders in primary care?BMC Fam Pract. (2015) 16:180. doi: 10.1186/s12875-015-0393-8
44.
Berezowski L Ludwig L Martin A Löwe B Shedden-Mora MC . Early psychological interventions for somatic symptom disorder and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med. (2022) 84:325–38. doi: 10.1097/PSY.0000000000001011
45.
Henningsen P Zipfel S Sattel H Creed F . Management of functional somatic syndromes and bodily distress. Psychother Psychosom. (2018) 87:12–31. doi: 10.1159/000484413
46.
Kohlmann S Löwe B Shedden-Mora MC . Health care for persistent somatic symptoms across Europe: a qualitative evaluation of the EURONET-SOMA expert discussion. Front Psych. (2018) 9:646. doi: 10.3389/fpsyt.2018.00646
47.
Van Dessel N Den Boeft M van der Wouden JC Kleinstäuber M Leone SS Terluin B et al . Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. (2014) 11:CD011142. doi: 10.1002/14651858.CD011142.pub2
48.
Rief W Burton C Frostholm L Henningsen P Kleinstauber M Kop WJ et al . Core outcome domains for clinical trials on somatic symptom disorder, bodily distress disorder, and functional somatic syndromes: European network on somatic symptom disorders recommendations. Psychosom Med. (2017) 79:1008–15. doi: 10.1097/PSY.0000000000000502
49.
What’s in the Psycho-Bundle? . A Systematic Review of Psychological Risk Factors in Persistent Somatic Symptoms. (2021). Available at: https://osf.io/anbm6. (Accessed March 10, 2023).
50.
Foster ED Deardorff A . Open science framework (OSF). J Med Libr Assoc. (2017) 105:203. doi: 10.5195/jmla.2017.88
51.
Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi: 10.1136/bmj.n71
52.
Thomas B Ciliska D Dobbins M Micucci S . A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid-Based Nurs. (2004) 1:176–84. doi: 10.1111/j.1524-475X.2004.04006.x
53.
Armijo-Olivo S Stiles CR Hagen NA Biondo PD Cummings GG . Assessment of study quality for systematic reviews: a comparison of the Cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research. J Eval Clin Pract. (2012) 18:12–8. doi: 10.1111/j.1365-2753.2010.01516.x
54.
Ouzzani M Hammady H Fedorowicz Z Elmagarmid A . Rayyan—a web and mobile app for systematic reviews. Syst Rev. (2016) 5:1–10. doi: 10.1186/s13643-016-0384-4
55.
R Core Team . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2022).
56.
Langan D Higgins JP Jackson D Bowden J Veroniki AA Kontopantelis E et al . A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. (2019) 10:83–98. doi: 10.1002/jrsm.1316
57.
Veroniki AA Jackson D Viechtbauer W Bender R Bowden J Knapp G et al . Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. (2016) 7:55–79. doi: 10.1002/jrsm.1164
58.
IntHout J Ioannidis J Borm GF . The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. (2014) 14:1–12. doi: 10.1186/1471-2288-14-25
59.
IntHout J Ioannidis JP Rovers MM Goeman JJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. (2016) 6:e010247. doi: 10.1136/bmjopen-2015-010247
60.
Booth A Clarke M Ghersi D Moher D Petticrew M Stewart L . An international registry of systematic-review protocols. Lancet. (2010) 377:108–9. doi: 10.1016/S0140-6736(10)60903-8
61.
Burton C Fink P Henningsen P Löwe B Rief W . Functional somatic disorders: discussion paper for a new common classification for research and clinical use. BMC Med. (2020) 18:1–7. doi: 10.1186/s12916-020-1505-4
62.
Fink P Schröder A . One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res. (2010) 68:415–26. doi: 10.1016/j.jpsychores.2010.02.004
63.
Kleinstäuber M Witthöft M Hiller W . Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev. (2011) 31:146–60. doi: 10.1016/j.cpr.2010.09.001
Summary
Keywords
persistent somatic symptoms, somatic symptom disorder, bodily distress disorder, functional somatic syndromes, psychological risk factors
Citation
Hüsing P, Smakowski A, Löwe B, Kleinstäuber M, Toussaint A and Shedden-Mora MC (2023) The framework for systematic reviews on psychological risk factors for persistent somatic symptoms and related syndromes and disorders (PSY-PSS). Front. Psychiatry 14:1142484. doi: 10.3389/fpsyt.2023.1142484
Received
11 January 2023
Accepted
16 March 2023
Published
05 April 2023
Volume
14 - 2023
Edited by
Heribert Christian Sattel, Technical University of Munich, Germany
Reviewed by
Seryan Atasoy, Technical University of Munich, Germany; Manfred Beutel, Johannes Gutenberg University Mainz, Germany
Updates
Copyright
© 2023 Hüsing, Smakowski, Löwe, Kleinstäuber, Toussaint and Shedden-Mora.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Paul Hüsing, p.huesing@uke.de
†These authors have contributed equally to this work and share senior authorship
This article was submitted to Psychological Therapy and Psychosomatics, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.